The global automated breast ultrasound market size was valued at USD 1.84 billion in 2023 and is projected to grow at a CAGR of 13.6% from 2024 to 2030. The increasing prevalence of breast cancer owing to a rise in sedentary lifestyle obesity, changes in eating habits, and rising alcohol consumption are expected to increase the risk of the disease. In addition, the demand for reliable identification of breast lesions in the early stage of cancer is encouraging major manufacturing companies to develop automated diagnosis methods. Furthermore, various other government initiatives and awareness programs by the government are significant contributing factors to the growth of the automated breast ultrasound market.
According to a report by the American Cancer Society, there were about 1.9 million people diagnosed with cancer in 2023. In addition, according to the WHO report published in March 2024, there were about 2.3 million women diagnosed with breast cancer and 670,000 deaths globally in 2022. This rise in the breast cancer cases would demand technologically advanced medical devices for easy and early detection compared to conventional methods. Thereby boosting the automated breast ultrasound market to grow positively over the forecast period.
The survival rate of breast cancer is significantly high when diagnosed in the early stages, but the rate drops to around 25 percent if detected in later stages. According to an article of the Massachusetts Institute of Technology published in July 2023; to improve the survival rate for breast cancer patients, researchers from MIT designed an ultrasound device that is wearable and can detect tumors in their early stages. Such technological advancements would boost the market growth positively over the forecast period.
Various initiatives undertaken by government institutions and companies have created awareness regarding breast cancer among men and women. This has fueled the market growth positively. For instance, the WHO launched a new roadmap on breast cancer targeting to save 2.5 million lives in 2023 from breast cancer by 2040. Similarly, the Ministry of Health and Family Welfare (Government of India) would provide financial assistance to people living below the poverty line and suffering from diseases such as cancer under the Umbrella scheme Rashtriya Arogya Nidhi and Health Minister’s Discretionary Grant.
Automated breast ultrasound dominated the market and accounted for a market share of 62.9% in 2023. It can be attributed to the user-friendly features of the device, its availability, and technological advancements. In addition, automated breast ultrasound offers comprehensive imaging of the breast, aiding in early detection, especially in dense breast tissue. It uses three-dimensional imaging techniques, which improve visualization and aid in accurate early detection. Thereby boosting the market growth. For instance, according to an article by GE Healthcare published in October 2023, the use of Invenia ABUS 2.0 has helped detect breast cancer with more accuracy. It can be attributed to the latest 3D ultrasound innovations and AI-based solutions, helping radiologists to thoroughly review all layers of dense tissue to identify breast cancers, particularly the small, invasive cancers that are normally missed by mammography.
Automated breast volume scanner is expected to grow at a significant CAGR during the forecast period. It can be attributed to the growing demand for automated solutions for early cancer detection. It can help bridge the gap of radiologists shortage by providing consistent and accurate results without the need for extensive operator expertise. Furthermore, the rising demand for advanced technological products for better diagnosis is anticipated to impede the segment growth. For instance, in February 2023, Abdul Latif Jameel Health partnered with iSono Health and introduced a 3D ultrasound breast imaging scanner that uses automated imaging and artificial intelligence and is portable.
Hospitals dominated the market and accounted for a market share of 48.4% in 2023. It can be attributed to the rising prevalence of breast cancer in recent times due to sedentary lifestyle. Hospitals are equipped with advanced diagnostic tools coupled with the availability of skilled healthcare professionals, leading to accuracy in the detection of cancer cases, thereby increasing patient footfalls and boosting segment growth. For instance, the Tata Trusts, India has Tata Memorial Hospital in Mumbai that helps in addressing the burden of cancer. The trusts also started an initiative to create awareness about the critical importance of early detection of breast cancer called “Gaanth Pe Dhyaan”.
Diagnostics imaging laboratories is expected to grow at the fastest CAGR during the forecast period. It can be attributed to the increasing number of diagnostic centers, the high prevalence of breast cancer, and the rising demand for imaging techniques for cancer treatment. All these factors have contributed for the segment growth over the forecast period.
North America automated breast ultrasound market dominated the global market with the revenue share of 35.3% in 2023. It can be attributed to the increasing prevalence of breast cancer and the presence of key market players in this region. In addition, the advanced healthcare infrastructure providing facilities for early cancer detection, and technological advancements coupled with research and development are the significant contributing factors for the market growth in this region. Furthermore, the government initiatives and funding/investments for creating awareness among people about breast cancer are boosting the market growth over the forecast period.
The U.S. automated breast ultrasound market dominated the global market with a share of 27.8% in 2023 owing to factors such as improved healthcare facilities and expenditure. Breast cancer is the second leading cause of cancer death. For instance, according to an article of the National Breast Cancer Foundation, Inc., published in July 2024, an estimated 42,250 women and 530 men would die from breast cancer in 2024 in the U.S. In addition, Cancer Moonshot is an initiative undertaken by the U.S. government to prevent more than 4 million cancer deaths by 2047 and to improve the experience of people who are touched by cancer.
Europe automated breast ultrasound market was identified as a lucrative region in 2023.It is attributed to the new technological advancements in this region. In addition, the growing prevalence of cancer, improved healthcare facilities, and focus on R&D have impacted the market growth. For instance, according to the EUROPA DONNA (The European Breast Cancer Coalition), the mortality of women in the WHO Europe Region, in 2022 was 16% due to breast cancer. ARENA launched a breast cancer awareness collection supporting the Keep A Breast Foundation to underscore the importance of early detection and access to timely, high-quality care and stand in support of survivors of breast cancer.
Asia Pacific automated breast ultrasound market is anticipated to witness significant growth in the automated breast ultrasound market. The rising burden of breast cancer leading to increased demand for innovative and technologically advanced cancer-detecting medical devices is the major contributing factor for the market growth in this region. For instance, according to the journal of the American Cancer Society published in January 2024, breast cancer deaths would increase to 61.7% by 2040 in the Southeast Asia region. In addition, an estimated 216,108 cases, accounting for 28.2% of all female cancers, occurred in India in 2022.
MEA automated breast ultrasound market is anticipated to witness significant growth in the automated breast ultrasound market. It can be attributed to the growing public awareness of breast cancer prevention and treatment. Demographic shifts in the Middle East and Africa, such as urbanization and lifestyle changes, may also contribute to the growing demand for automated breast ultrasound, thereby increasing the market growth in this region. The UAE has a significant track record for accelerated approval of cancer drugs. For instance, in September 2022, the UAE became the first country in the MENA region to approve abemaciclib drug for adjuvant therapy in high-risk hormone-positive, HER2-negative early BC for this indication.
Some of the key companies in the automated breast ultrasound market include GE HealthCare., Koninklijke Philips N.V., Siemens Healthcare Private Limited, Canon Medical Systems Corporation and others These companies are growing their market revenue by launching new products, collaborations and adopting various other strategies.
Delphinus Medical Technologies, Inc. is a Novi, Michigan-based company dealing with automated breast ultrasound, offering advanced solutions for dense breast screening. It aims to help in the early detection of breast cancer and deliver medical innovations to improve screening and detection.
GE HealthCare. is a global medical technology company that engages in manufacturing and distribution of diagnostic imaging and clinical systems. The company developed Invenia Automated Breast Ultrasound (ABUS) system, which helps in enhanced breast cancer detection, particularly in women with dense breast tissue.
The following are the leading companies in the automated breast ultrasound market. These companies collectively hold the largest market share and dictate industry trends.
In July 2024, Delphinus Medical Technologies, Inc. installed SoftVue breast ultrasound tomography at West Jefferson Medical Center in Louisiana.
In May 2022, iSono Health received US FDA clearance for the ATUSA System, a portable breast imaging system.
Report Attribute |
Details |
Market size value in 2024 |
USD 2.09 billion |
Revenue forecast in 2030 |
USD 4.49 billion |
Growth rate |
CAGR of 13.6% from 2024 to 2030 |
Base year for estimation |
2023 |
Historical data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, end use, region |
Regional scope |
North America, Europe, Asia Pacific, Latin America, MEA |
Country scope |
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, Japan, China, India, Australia, South Korea, Thailand, Brazil, Argentina, KSA, UAE, South Africa, Kuwait |
Key companies profiled |
GE HealthCare., Koninklijke Philips N.V., Siemens Healthcare Private Limited, CANON MEDICAL SYSTEMS CORPORATION, TELEMED Medical Systems srl, Hologic, Inc., SuperSonic Imagine, Lunit Inc., Delphinus Medical Technologies, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global automated breast ultrasound market report based on product, end use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Automated Breast Volume Scanner
Automated Breast Ultrasound (ABUS)
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospital
Diagnostics Imaging Laboratories
Others
Regional Outlook (Revenue, USD Million; 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."